Bernstein SocGen raises Edwards Lifesciences stock price target to $96 By Investing.com

Bernstein SocGen raised its price target on Edwards Lifesciences to $96 from $95 while keeping a Market Perform rating, following a strong Q1 print. Revenue rose to $1.65 billion, up 16.7% year over year and 12.7% organically, beating consensus by 3%, while adjusted EPS of $0.78 beat estimates by 7% and adjusted operating margin improved to 31.4% (+190 bps vs consensus). The quarter was driven by broad-based strength, especially TAVR sales of $1.197 billion, prompting multiple analyst target increases despite mixed rating actions.

Analysis

EW’s print improves the probability that the market has been discounting too much margin compression from the current investment cycle. The more important signal is not the beat itself, but that multiple franchises are now contributing simultaneously, which usually precedes a period of estimate re-rating rather than just one-quarter relief. If management can sustain this cadence while phasing spend, the street likely has room to lift medium-term EPS by another high-single-digit to low-double-digit percentage over the next 2-3 quarters.

The competitive read-through is more interesting than the stock move: a clean TAVR/TMTT quarter implies EW is still taking share in structural heart, and that pressures smaller device peers that have not yet proven they can match both growth and operating leverage. The second-order effect is on hospital purchasing behavior — once a platform vendor demonstrates breadth plus execution, system-level consolidation tends to favor the incumbent, making displacement harder for challengers over the next 12-18 months.

The main risk is that this is being mistaken for a durable acceleration when it may partly reflect timing of investments and a favorable comparison base. That matters because valuation already assumes persistence; if growth normalizes even modestly in the next two quarters, multiple expansion could stall quickly. The contrarian view is that the real upside may come from earnings power, not revenue, and the market is still underappreciating how much operating leverage can emerge if spend discipline continues into 2026.

For holders, the setup is constructive but not “chaseable” after a strong fundamental report in a still-expensive multiple band. The better trade is to own it through the next catalyst cycle and use any post-earnings vol compression to add rather than paying up into strength. On the other hand, if the stock starts trading like a pure growth compounder without continued margin evidence, that is a signal the move has outrun fundamentals.

Key Decisions for Investors

• Long EW on pullbacks over the next 1-3 weeks; target a 10-15% rerating if the market starts capitalizing sustained margin consistency, with a stop if the next quarter shows any deceleration in operating leverage.
• Use EW calls rather than stock for the next 2-4 months if implied vol remains elevated; upside is best captured on further estimate revisions, while downside is bounded if the quarter was a one-off timing benefit.
• Pair trade: long EW / short a weaker structural-heart competitor basket over the next 3-6 months; thesis is share concentration around the highest-execution platform, with alpha driven by recurring hospital procurement wins.
• If EW trades above the current forward multiple without upward EPS revisions over the next quarter, trim 25-30% of exposure; the valuation already leaves limited room for multiple-only gains.